article thumbnail

Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions

TechCrunch

Neuroglee Therapeutics , a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. million to develop digital therapeutics for neurodegenerative diseases. Neuroglee gets $2.3

article thumbnail

Biofourmis hits unicorn status after $300m Series D funding

AsiaTechDaily

Register Biofourmis , a Sigapore-founded digital therapeutics firm , announced that it has surpassed unicorn status with a $300 million Series D investment led by leading global growth equity firm General Atlantic. Bookmark ( 0 ) Please login to bookmark Username or Email Address Password Remember Me No account yet?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BrainCheck brings in another $10M to detect, manage cognitive impairment

TechCrunch

BrainCheck , a Houston- and Austin-based company developing cognitive healthcare software to aid physicians in detecting and managing this type of care, raised $10 million in Series B funding to expand its R&D and go-to-market capabilities as it works on new digital therapeutics for Alzheimer’s and related dementias.

article thumbnail

NJEDA Names Inaugural New Jersey Innovation Fellows Cohort

American Entrepreneurship

in income replacement grants and mentorship to first-time entrepreneurs, creating 10 new businesses and helping fuel innovation in strategic sectors The New Jersey Economic Development Authority (NJEDA) today announced the inaugural cohort of the New Jersey Innovation Fellows (NJIF) program. First-in-nation program will provide $3.6M

article thumbnail

FDA: Orientation for Early Stage Startups

Y Combinator

The FDA is the federal regulatory body in the United States that oversees the development of medical products (e.g. Developing and bringing a product to market will, with the exception of a limited class of products 1 , require explicit FDA marketing approval. We describe the major ones here: Therapeutic Submissions.

startup 59